Review of bemiparin sodium – a new second-generation low molecular weight heparinand its applications in venous thromboembolism

@article{Plans2003ReviewOB,
  title={Review of bemiparin sodium – a new second-generation low molecular weight heparinand its applications in venous thromboembolism},
  author={Andr{\'e} Plan{\`e}s},
  journal={Expert Opinion on Pharmacotherapy},
  year={2003},
  volume={4},
  pages={1551 - 1561}
}
  • A. Planès
  • Published 1 September 2003
  • Medicine
  • Expert Opinion on Pharmacotherapy
Bemiparin sodium (Hibor®, Ivor®, Zivor®, Badyket®, Laboratorios Farmaceuticos Rovi SA) is a new second-generation low molecular weight heparin (LMWH). Bemiparin has the lowest mean molecular weight (3600 Da), the longest half-life (5.3 h) and the largest antifactor Xa:antifactor IIa ratio (8:1) of all LMWHs. Bemiparin promotes a greater release of tissue factor pathway inhibitor than unfractionated heparin (UFH) or dalteparin. These properties could result in a more favourable efficacy:safety… 
Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism
TLDR
Results from multicenter pharmacoeconomic studies in the Spanish Health Care System indicate that bemiparin is more cost effective than enoxaparin for the prevention of VTE in total knee replacement and may be a safe, cost-saving alternative to unfractionated heparin in the short-term treatment of Vte, and a safe cost-neutral alternative to oral anticoagulant therapy in long- term treatment.
New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin
TLDR
Results from ongoing trials could be critical to establish the potential of bemiparin in oncological patients since international guidelines recommend LMWHs for initial and continuous anticoagulant treatment in cancer patients with VTE, as well as for its prevention.
Bemiparin: pharmacological profile.
TLDR
Bemiparin increased the release and activity of tissue factor pathway inhibitor (TFPI) from endothelial cells under both static conditions and arterial sheer stress and has good antithrombotic activity and a better pharmacological profile than unfractionated heparin.
Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis
TLDR
Bemiparin plus OAC or long-term bemiparin for 3 months may be dominant strategies over UFHplus OAC in the treatment of DVT from the Spanish National Health System perspective, offering better outcomes and cost savings.
Thromboprophylaxis with the Low-Molecular-Weight Heparin Bemiparin Sodium in Elderly Medical Patients in Usual Clinical Practice
TLDR
Bemiparin sodium thromboprophylaxis for 4–5 weeks was associated with a low incidence of VTE and a low rate of bleeding and other complications in non-surgical elderly patients at risk of V TE, treated either in GCs or in HHUs, in standard clinical practice.
Pharmacoeconomic Analysis of Bemiparin and Enoxaparin as Prophylaxis for Venous Thromboembolism in Total Knee Replacement Surgery
TLDR
The model suggests that bemiparin may be more cost effective than enoxaparin for thromboprophylaxis in total knee replacement surgery in the Spanish healthcare setting.
Low-Molecular-Weight Heparins: Before or After Surgery? New Concepts and Evidence
TLDR
Of particular interest were the issues debated during the Sigma Tau/ROVI Satellite Symposium, which focused on the optimal timing strategy for initiating thromboprophylaxis in patients undergoing orthopaedic surgery.
Bemiparin Versus Unfractionated Heparin as Bridging Therapy in the Perioperative Management of Patients on Vitamin K Antagonists: The BERTA Study
TLDR
Despite its small size, the BERTA study is the first randomised, double-blind clinical trial comparing UFH with a fixed high-risk thromboprophylactic dose of an LMWH as bridging therapy and suggests that bemiparin is at least as safe as UFH as bridges therapy.
Cost–effectiveness of bemiparin in the prevention and treatment of venous thromboembolism
TLDR
Bemiparin may be a safer and cost-neutral alternative to oral anticoagulants for long-term treatment (secondary prophylaxis) of venous thromboembolism.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 68 REFERENCES
Reviparin sodium – a new low molecular weight heparin
  • H. Breddin
  • Medicine
    Expert opinion on pharmacotherapy
  • 2002
TLDR
Reviparin has been shown to be as effective as UFH in different prophylactic indications and causes fewer injection-site haematomas and the use of reviparin is associated with a similar or lower incidence of bleeding complications than UFH.
Comparison of two low‐molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery
TLDR
The two treatment groups were clinically equivalent in efficacy, and the reviparin-treated patients had fewer haematomas, bruisings and higher red cell counts and lower haemoglobin levels than the enoxaparin- treated patients.
Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure.
TLDR
The findings suggest that a hypercoagulable state in heart failure can be modified with bemiparin sodium therapy.
Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
TLDR
This study aimed to compare the efficacy and safety of unfractionated (UF) heparin with that of a low molecular weight Heparin (Fragmin, Kabi Pharmacia) in the prevention of recurrent deep venous thrombosis (DVT) and pulmonary embolism (PE) in a consecutive series of patients with contraindications to coumarin therapy.
A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
TLDR
Whether the demonstrated differences in anti-Xa and anti-II activities are of any clinical significance remains unclear and can only be established by comparative clinical studies, although unknown which activity/activities are best correlated to efficacy.
Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
TLDR
Dalteparin, nadroparin and enoxaparin exhibit statistically significantly different pharmacokinetic and overall disposition patterns, which may contribute to explain the different safety/efficacy balance of each of these antithrombotic medications.
Elevation of Hepatic Transaminases after Enoxaparin Use: Case Report and Review of Unfractionated and Low‐Molecular‐Weight Heparin‐Induced Hepatotoxicity
TLDR
The distinctive characteristics of LMWHs have resulted in decreased rates of bleeding and equivalent rates of thrombocytopenia compared with unfractionated heparin, and may have led clinicians to believe that LM WHs have lower frequencies of all common side effects.
Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis.
TLDR
Both bemiparin regimens were more effective than UFH in reducing thrombus size during the acute phase of treatment and Bemiparin is also an effective alternative to warfarin for long-term treatment.
Low-molecular-weight heparin.
  • J. Nunnelee
  • Medicine
    Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing
  • 1997
Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis
TLDR
A meta-analysis to incorporate the most recent data from clinical trials, to resolve discrepancies among previous reviews, and to obtain precise estimates of clinically important treatment outcomes is performed.
...
1
2
3
4
5
...